Related Experiment Videos
Current developments in thrombolytic therapy using novel plasminogen activators
1Abteilung Innere Medizin III, Medizinische Klinik und Poliklinik der Universität Ulm, Fed. Rep. of Germany.
Abstract:
As a result of intensive recent research, the molecular mechanisms governing the human fibrinolytic system could be elucidated. Clinical trials using streptokinase and urokinase demonstrated that therapeutic thrombolysis is a valuable regimen in the treatment of patients with thromboembolic diseases. After unsuccessful attempts to increase the clot specificity of these agents, efforts were increased towards developing fibrin-specific substances with high thrombolytic potency and negligible effects on systemic hemostasis. Tissue-type plasminogen activator manufactured by recombinant DNA technology (rt-PA) is currently the most comprehensively investigated fibrin-specific thrombolytic agent with the most clearly understood mechanism of action in vivo. Pro-urokinase has also become available through biotechnology. A large number of clinical trials studying thrombolytic therapy of myocardial infarction have proved that intravenous rt-PA posesses superior efficacy compared to conventional fibrinolytic agents. Comparatively few clinical studies have been performed using pro-urokinase. At therapeutic doses, the fibrin specificities of these agents differ. So far it has not been possible to correlate the incidence of bleeding complications during fibrinolytic therapy with alterations in hemostasis parameters. For routine laboratory monitoring of thrombolysis the determination of fibrinogen and thrombin clotting time can be recommended. New developments with potential for yielding the next generation of thrombolytic agents are mutants and chimeras of t-PA and pro-urokinase, and conjugates of these substances with fibrin specific antibodies.
Insights
New fibrin-specific thrombolytic agents like recombinant tissue-type plasminogen activator (rt-PA) show superior efficacy in treating myocardial infarction. Further research focuses on developing next-generation agents for improved thrombolysis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The human fibrinolytic system's molecular mechanisms have been elucidated through recent research.
- Therapeutic thrombolysis using streptokinase and urokinase is established for thromboembolic diseases.
- There is a need for fibrin-specific thrombolytic agents with high potency and minimal systemic hemostasis effects.
Purpose of the Study:
- To review the development and efficacy of fibrin-specific thrombolytic agents.
- To compare the clinical performance of recombinant tissue-type plasminogen activator (rt-PA) and pro-urokinase.
- To discuss future directions in thrombolytic agent development.
Main Methods:
- Review of clinical trials and scientific literature on thrombolytic therapy.
- Analysis of mechanisms of action and efficacy of rt-PA and pro-urokinase.
- Examination of bleeding complications and laboratory monitoring in thrombolysis.
Main Results:
- Intravenous rt-PA demonstrates superior efficacy in myocardial infarction treatment compared to conventional agents.
- Pro-urokinase has been less extensively studied clinically.
- Fibrin specificities of therapeutic agents differ, and bleeding complications are not clearly correlated with hemostasis parameters.
- Fibrinogen and thrombin clotting time are recommended for laboratory monitoring.
Conclusions:
- rt-PA is a highly effective fibrin-specific thrombolytic agent for myocardial infarction.
- Next-generation thrombolytic agents include mutants, chimeras, and antibody conjugates of t-PA and pro-urokinase.
- Continued research aims to enhance thrombolytic potency and specificity while minimizing bleeding risks.